Part 10: Acute Coronary Syndromes

2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Robert E. O’Connor, Chair; William Brady; Steven C. Brooks; Deborah Diercks; Jonathan Egan; Chris Ghaemmaghami; Venu Menon; Brian J. O’Neil; Andrew H. Travers; Demetris Yannopoulos

The 2010 AHA Guidelines for CPR and ECC for the evaluation and management of acute coronary syndromes (ACS) are intended to define the scope of training for healthcare providers who treat patients with suspected or definite ACS within the first hours after onset of symptoms. These guidelines summarize key out-of-hospital, emergency department (ED), and related initial critical-care topics that are relevant to diagnosis and initial stabilization and are not intended to guide treatment beyond the ED. Emergency providers should use these contents to supplement other recommendations from the ACC/AHA Guidelines, which are used throughout the United States and Canada.1–3 As with any guidelines, these general recommendations must be considered within the context of local resources and their application to individual patients by knowledgeable healthcare providers. The healthcare providers managing the individual patients are best suited to determine the most appropriate treatment strategy.

The primary goals of therapy for patients with ACS are to

- Reduce the amount of myocardial necrosis that occurs in patients with acute myocardial infarction (AMI), thus preserving left ventricular (LV) function, preventing heart failure, and limiting other cardiovascular complications
- Prevent major adverse cardiac events (MACE): death, nonfatal MI, and need for urgent revascularization
- Treat acute, life-threatening complications of ACS, such as ventricular fibrillation (VF), pulseless ventricular tachycardia (VT), unstable tachycardias, symptomatic bradycardias (See Part 8: “Advanced Cardiovascular Life Support”), pulmonary edema, cardiogenic shock and mechanical complications of AMI
- An overview of recommended care for the ACS patient is illustrated in Figure 1, the Acute Coronary Syndromes Algorithm. Part 10 provides details of the care highlighted in the numbered algorithm boxes; box numbers in the text correspond to the numbered boxes in the algorithm. In this part, the abbreviation “AMI” refers to acute myocardial infarction, whether associated with ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). The diagnosis and treatment of AMI, however, will often differ for patients with STEMI versus NSTEMI. Please note carefully which AMI type is being discussed.

Prehospital Management

Patient and Healthcare Provider Recognition of ACS (Figure 1, Box 1)

Prompt diagnosis and treatment offers the greatest potential benefit for myocardial salvage in the first hours of STEMI; and early, focused management of unstable angina and NSTEMI reduces adverse events and improves outcome.4 Thus, it is imperative that healthcare providers recognize patients with potential ACS in order to initiate the evaluation, appropriate triage, and management as expeditiously as possible; in the case of STEMI, this recognition also allows for prompt notification of the receiving hospital and preparation for emergent reperfusion therapy. Potential delays to therapy occur during 3 intervals: from onset of symptoms to patient recognition, during prehospital transport, and during emergency department (ED) evaluation.

Patient-based delay in recognition of ACS and activation of the emergency medical services (EMS) system often constitutes the longest period of delay to treatment.5 With respect to the prehospital recognition of ACS, numerous issues have been identified as independent factors for prehospital treatment delay (ie, symptom-to-door time), including older age,6 racial and ethnic minorities,7,8 female gender,9 lower socioeconomic status,10,11 and solitary living arrangements.7,12

Hospital-based delays in ACS recognition range from nonclassical patient presentations and other confounding diagnostic issues to provider misinterpretation of patient data and inefficient in-hospital system of care.9,13–16

Symptoms of ACS may be used in combination with other important information (biomarkers, risk factors, ECG, and other diagnostic tests) in making triage and some treatment decisions in the out-of-hospital and ED settings. The symptoms of AMI may be more intense than angina and most often
Persist for longer periods of time (e.g., longer than 15–20 minutes). The classic symptom associated with ACS is chest discomfort, but symptoms may also include discomfort in other areas of the upper body, shortness of breath, sweating, nausea, vomiting, and dizziness. Most often the patient will note chest or upper body discomfort and dyspnea as the predominant presenting symptoms accompanied by diaphoresis, nausea, vomiting, and dizziness. Isolated diaphoresis, nausea, vomiting, or dizziness are unusual predominant presenting symptoms. Atypical or unusual symptoms are
more common in women, the elderly, and diabetic patients. The physical examination of the patient with ACS is often normal.

Public education campaigns increase patient awareness and knowledge of the symptoms of ACS, yet have only transient effects on time to presentation. For patients at risk for ACS (and for their families), primary care physicians and other healthcare providers should consider discussing the appropriate use of aspirin and activation of EMS system. Furthermore, an awareness of the location of the nearest hospital that offers 24-hour emergency cardiovascular care can also be included in this discussion. Previous guidelines have recommended that the patient, family member, or companion activate the EMS system rather than call their physician or drive to the hospital if chest discomfort is unimproved or worsening 5 minutes after taking 1 nitroglycerin treatment.

**Initial EMS Care (Figure 1, Box 2)**

Half the patients who die of ACS do so before reaching the hospital. VF or pulseless VT is the precipitating cardiac arrest rhythm in most of these deaths, and it is most likely to develop in the early phase of ACS evolution. Communities should develop programs to respond to cardiac emergencies that include the prompt recognition of ACS symptoms by patients and their companions as well as by healthcare and public safety providers and early activation of the EMS system. Additional features of such a program include high-quality CPR for patients in cardiac arrest (see Part 5: “Adult Basic Life Support”) and rapid access to and use of an automated external defibrillator (AED) through community AED programs (see Part 6: “Electrical Therapies”). Emergency dispatch center personnel should be educated in the provision of CPR instructions for lay rescuers before the arrival of EMS. EMS providers should be trained to respond to cardiovascular emergencies, including ACS and its acute complications.

Emergency dispatch center personnel can provide instructions to the patient or caller before EMS arrival. Because aspirin should be administered as soon as possible after symptom onset to patients with suspected ACS, it is reasonable for EMS dispatchers to instruct patients with no history of aspirin allergy and without signs of active or recent gastrointestinal bleeding to chew an aspirin (160 to 325 mg) while awaiting the arrival of EMS providers (Class IIa, LOE C).  

EMS providers should be familiar with the presentation of ACS and trained to determine the time of symptom onset. EMS providers should monitor vital signs and cardiac rhythm and be prepared to provide CPR and defibrillation if needed.

![Prehospital Fibrinolytic Checklist](image)

**Figure 2.** Prehospital fibrinolytic checklist. Adapted from Antman EM, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82-e292, with permission from Lippincott Williams & Wilkins.

Copyright 2004, American Heart Association.
EMS providers administer oxygen during the initial assessment of patients with suspected ACS. However, there is insufficient evidence to support its routine use in uncomplicated ACS. If the patient is dyspneic, hypoxic, or has obvious signs of heart failure, providers should titrate therapy, based on monitoring of oxyhemoglobin saturation, to ≥94% (Class I, LOE C).36

EMS providers should administer nonenteric aspirin (160 [Class I, LOE B] to 325 mg [Class I, LOE C]). The patient should chew the aspirin tablet to hasten absorption.30,37–39 EMS providers should administer up to 3 nitroglycerin doses (tablets or spray) at intervals of 3 to 5 minutes. Nitrates in all forms are contraindicated in patients with initial systolic blood pressure <90 mm Hg or ≥30 mm Hg below baseline and in patients with right ventricular involvement.40–42 Caution is advised in patients with known inferior wall STEMI, and a right-sided ECG should be performed to evaluate RV infarction. Administer nitrates with extreme caution, if at all, to patients with inferior STEMI and suspected right ventricular (RV) involvement because these patients require adequate RV preload. Nitrates are contraindicated when patients have taken a phosphodiesterase-5 (PDE-5) inhibitor within 24 hours (48 hours for tadalafil).41 Morphone is indicated in STEMI when chest discomfort is unresponsive to nitrates (Class I, LOE C); morphine should be used with caution in unstable angina (UA)/NSTEMI due to an association with increased mortality in a large registry (Class IIa, LOE C).44 The efficacy of other analgesics is unknown.

**Prehospital ECGs (Figure 1, Box 2)**

Prehospital 12-lead ECGs speed the diagnosis, shorten the time to reperfusion (fibrinolitics45–52 or primary percutaneous coronary intervention [PCI]53–60). EMS personnel should routinely acquire a 12-lead electrocardiogram (ECG) as soon as possible for all patients exhibiting signs and symptoms of ACS. The ECG may be transmitted for remote interpretation by a physician or screened for STEMI by properly trained paramedics, with or without the assistance of computer-interpretation. Advance notification should be provided to the receiving hospital for patients identified as having STEMI (Class I, LOE B).

Implementation of 12-lead ECG diagnostic programs with concurrent medically-directed quality assurance is recommended (Class I, LOE B). Prehospital personnel can accurately identify ST-segment elevation from the 12-lead ECG.47,50,61–74 If providers are not trained to interpret the 12-lead ECG, field transmission of the ECG or a computer report to the receiving hospital is recommended (Class I, LOE B).

**Prehospital Fibrinolysis**

Clinical trials have shown the benefit of initiating fibrinolysis as soon as possible after onset of ischemic-type chest discomfort in patients with confirmed STEMI or new or presumably new left bundle branch block (LBBB).75,76 Several prospective studies77–79 have documented reduced time to administration of fibrinolytics and decreased mortality rates when out-of-hospital fibrinolitics were administered to patients with STEMI. Physicians in the Grampian Region Early Anistreplase Trial (GREAT) trial administered fibrinolytic therapy to patients at home 130 minutes earlier than to patients at the hospital with both a 50% reduction in hospital mortality and greater 1-year and 5-year survival in those treated earlier.79–81 Meta-analyses have demonstrated reduced mortality and improved outcomes with prehospital fibrinolysis regardless of the training and experience of the prehospital provider.75,77

When fibrinolysis is the chosen reperfusion strategy the fibrinolytic agent should be initiated as soon as possible, preferably within 30 minutes of first medical contact (Class I, LOE A). It is strongly recommended that systems which administer fibrinolitics in the prehospital setting include the following features: protocols using fibrinolytic checklists, 12-lead ECG acquisition and interpretation, experience in advanced life support, communication with the receiving institution, medical director with training and experience in STEMI management, and continuous quality improvement (Class I, LOE C).

**Triage and Transfer**

**Prehospital Triage and EMS Hospital Destination**

In approximately 40% of patients with a myocardial infarction, the EMS provider establishes first medical contact.82,83 In these patients, the ability to identify STEMI in the prehospital setting allows for the consideration of specific hospital destination. Direct triage from the scene to a PCI-capable hospital may reduce the time to definitive therapy and improve outcome. In a large historically controlled clinical trial, the mortality rate was significantly reduced (8.9% versus 1.9%) when transport time was less than 30 minutes.84 Increased out-of-hospital times with longer EMS-initiated diversion to a PCI-capable hospital may worsen outcomes. If PCI is the chosen method of reperfusion for the prehospital STEMI patient, it is reasonable to transport patients directly to the nearest PCI facility, bypassing closer EDs as necessary, in systems where time intervals between first medical contact and balloon times are <90 minutes and transport times are relatively short (ie, <30 minutes) (Class IIa, LOE B).

In patients presenting within 2 hours of symptom onset or when delays to PCI are anticipated, fibrinolytic therapy is recommended. In these circumstances fibrinolytic therapy has equivalent or improved outcomes compared to PCI, especially when the benefit to bleeding risk is favorable (eg, young age, anterior location of MI) (Class I, LOE C).85,86

**Interfacility Transfer**

Hospital and ED protocols should clearly identify criteria for expeditious transfer of patients to PCI facilities. These include patients who are ineligible for fibrinolytic therapy or who are in cardiogenic shock (Class I, LOE C). A door-to-departure time <30 minutes is recommended by ACC/AHA Guidelines.2 Transfer of high-risk patients who have received primary reperfusion with fibrinolytic therapy is reasonable (Class IIa, LOE B).87,88

**Systems of Care**

A well-organized approach to STEMI care requires integration of community, EMS, physician, and hospital resources.
The most appropriate STEMI system of care starts “on the phone” with activation of EMS. Hospital-based issues include ED protocols, activation of the cardiac catheterization laboratory, and admission to the coronary intensive care unit.

In PCI-capable hospitals an established “STEMI Alert” activation plan is critical. Components include prehospital ECGs and notification of the receiving facility,45–60 and activation of the cardiac catheterization team to shorten reperfusion time54,59,82,89–92 and other hospital personnel important for treatment and resource allocation.

Continuous review and quality improvement involving EMS and prehospital care providers are important to achieve ongoing optimal reperfusion time. Quality assurance, real-time feedback, and healthcare provider education can also reduce the time to therapy in STEMI.89,93–97 Involvement of hospital leadership in the process and commitment to support rapid access to STEMI reperfusion therapy are critical factors associated with successful programs.

If the emergency physician activates the STEMI reperfusion protocol, including the cardiac catheterization team, significant reductions in time to reperfusion are seen, and the rate of “false-positive” activations are infrequent, ranging from 0% to 14%.89,93,95,96,98–107

ED Evaluation and Risk Stratification (Figure 1, Boxes 3 and 4)
Focused Assessment and ECG Risk Stratification
ED providers should quickly assess patients with possible ACS. Ideally within 10 minutes of ED arrival providers should obtain a targeted history while a monitor is attached to the patient and a 12-lead ECG is obtained (if not done in the prehospital setting).108 The evaluation should focus on chest discomfort, associated signs and symptoms, prior cardiac history, risk factors for ACS, and historical features that may preclude the use of fibrinolytics or other therapies. This initial evaluation must be efficient because if the patient has STEMI, the goals of reperfusion are to administer fibrinolytics within 30 minutes of arrival (30-minute interval “door-to-data”), and to provide PCI within 90 minutes of arrival (90-minute interval “door-to-balloon”) (Class I, LOE A).

Potential delay during the in-hospital evaluation period may occur from door to data, from data (ECG) to decision, and from decision to drug (or PCI). These 4 major points of in-hospital therapy are commonly referred to as the “4 D’s.”109 All providers must focus on minimizing delays at each of these points. Prehospital transport time constitutes only 5% of delay to treatment time; ED evaluation constitutes 25% to 33% of this delay.3,109–111

The physical examination is performed to aid diagnosis, rule out other causes of the patient’s symptoms, and evaluate the patient for complications related to ACS. Although the presence of clinical signs and symptoms may increase suspicion of ACS, evidence does not support the use of any single sign or combination of clinical signs and symptoms alone to confirm the diagnosis.17–19,112

When the patient presents with symptoms and signs of potential ACS, the clinician uses ECG findings (Figure 1, Box 4) to classify the patient into 1 of 3 groups:

1. ST-segment elevation or presumed new LBBB (Box 5) is characterized by ST-segment elevation in 2 or more contiguous leads and is classified as ST-segment elevation MI (STEMI). Threshold values for ST-segment elevation consistent with STEMI are J-point elevation 0.2 mV (2 mm) in leads V2 and V3 and 0.1 mV (1 mm) in all other leads (men ≥40 years old); J-point elevation 0.25 mV (2.5 mm) in leads V2 and V3 and 0.1 mV (1 mm) in all other leads (men <40 years old); J-point elevation 0.15 mV (2.5 mm) in leads V2 and V3 and 0.1 mV (1 mm) in all other leads (women).113

2. Ischemic ST-segment depression >0.5 mm (0.05 mV) or dynamic T-wave inversion with pain or discomfort (Box 9) is classified as UA/NSTEMI. Nonpersistent or transient ST-segment elevation ≥0.5 mm for <20 minutes is also included in this category. Threshold values for ST-segment depression consistent with ischemia are J-point depression 0.05 mV (0.5 mm) in leads V2 and V3 and -0.1 mV (-1 mm) in all other leads (men and women).113

3. The nondiagnostic ECG with either normal or minimally abnormal (ie, nonspecific ST-segment or T-wave changes, Box 13). This ECG is nondiagnostic and inconclusive for ischemia, requiring further risk stratification. This classification includes patients with normal ECGs and those with ST-segment deviation of <0.5 mm (0.05 mV) or T-wave inversion of ≤0.2 mV. This category of ECG is termed nondiagnostic.

The interpretation of the 12-lead ECG is a key step in this process, allowing not only for this classification but also the selection of the most appropriate diagnostic and management strategies. Not all providers are skilled in the interpretation of the ECG; as a consequence, the use of computer-aided ECG interpretation has been studied. While expert ECG interpretation is ideal, computer-aided ECG interpretation may have a role, particularly in assisting inexperienced clinicians in achieving a diagnosis (Class IIa, LOE B).

Cardiac Biomarkers
Serial cardiac biomarkers are often obtained during evaluation of patients suspected of ACS. Cardiac troponin is the preferred biomarker and is more sensitive than creatine kinase isoenzyme (CK-MB). Cardiac troponins are useful in diagnosis, risk stratification, and determination of prognosis. An elevated level of troponin correlates with an increased risk of death, and greater elevations predict greater risk of adverse outcome.114

In the patients with STEMI reperfusion therapy should not be delayed pending results of biomarkers. Important limitations to these tests exist because they are insensitive during the first 4 to 6 hours of presentation unless continuous persistent pain has been present for 6 to 8 hours. For this reason cardiac biomarkers are not useful in the prehospital setting.115–120

Clinicians should take into account the timing of symptom onset and the sensitivity, precision, and institutional norms of the assay, as well as the release kinetics and clearance of the measured biomarker. If biomarkers are initially negative within 6 hours of symptom onset, it is recommended that biomarkers should be remeasured between 6 to 12 hours after symptom onset (Class I, LOE A). A diagnosis of myocardial
infarction can be made when clinical symptoms or new ECG abnormalities are consistent with ischemia and one biomarker is elevated above the 99th percentile of the upper reference limit (URL) using a test with optimal precision defined as a CV ≤10%.

There is insufficient evidence to support the use of troponin point-of-care testing (POCT) either in or out of hospital. There is also insufficient evidence to support the use of myoglobin, β-natriuretic peptide (BNP), NT-proBNP, D-dimer, C-reactive protein, ischemia-modified albumin pregnancy-associated plasma protein A (PAPP-A) or interleukin-6 in isolation.

**STEMI (Figure 1, Boxes 5 Through 8)**

Patients with STEMI usually have complete occlusion of an epicardial coronary artery. The primary goal of initial treatment is early reperfusion therapy through administration of fibrinolytics (pharmacological reperfusion) or PCI (mechanical reperfusion). Providers should rapidly identify patients with STEMI and quickly screen them for indications and contraindications to fibrinolytic therapy and PCI. Patients who are ineligible for fibrinolytic therapy should be considered for transfer to a PCI facility regardless of delay.

Within a STEMI system of care, the first physician who encounters a patient with STEMI determines the need and strategy (fibrinolytic or PCI) for reperfusion therapy (see Table 1). If the patient meets the criteria for fibrinolytic therapy, a door-to-needle time (initiation of fibrinolytic agent) ≤30 minutes is recommended—the earlier the better (Class I, LOE A). Routine consultation with a cardiologist or another physician is not recommended except in equivocal or uncertain cases. Consultation delays therapy and is associated with increased hospital mortality rates (Class III, LOE B).

**UA and NSTEMI (Figure 1, Boxes 9 Through 12)**

Unstable angina (UA) and NSTEMI are difficult to distinguish initially. These patients usually have a partially or intermittently occluding thrombus. Both ACS syndromes may present with similar symptoms and ECG. Clinical features can correlate with the dynamic nature of clot formation and degradation (eg, waxing and waning clinical symptoms). The ECG will demonstrate a range of findings short of diagnostic ST-segment deviation; these ECG presentations include normal, minimal nonspecific ST-segment/T-wave changes, and significant ST-segment depression and T-wave inversions.

An elevated biomarker separates NSTEMI from UA and has incremental value in addition to the ECG. Elevation of cardiac troponin indicates increased risk for major adverse cardiac events and benefit from an invasive strategy. Cardiac troponins indicate myocardial necrosis, although numerous conditions other than ACS may cause elevated biomarkers (eg, myocarditis, heart failure, and pulmonary embolism).

Management strategies for UA/NSTEMI include antiplatelet, antithrombin, and antiangiinal therapy and are based on risk stratification. Fibrinolysis is contraindicated in this heterogenous group of patients and may be harmful; an invasive strategy is indicated in patients with positive biomarkers or unstable clinical features.

### The Process of Risk Stratification

Diagnosis of ACS and risk stratification become an integrated process in patients presenting to an acute care setting with possible ACS and an initially nondiagnostic evaluation. This nondiagnostic evaluation includes a normal or nondiagnostic 12-lead ECG and normal serum cardiac biomarker concentrations. The majority of these patients will not be experiencing an ACS, but many may have underlying CAD or other clinical features putting them at subsequent risk for major adverse cardiac events over the course of a few days to several months.

A major goal of the risk stratification process is to identify those patients who do not appear to have high-risk features on initial assessment but are found, through the course of the diagnostic process, to have ACS and clinically significant CAD. This strategy allows physicians to target patients who would benefit from guidelines-based ACS therapies while avoiding unnecessary procedural and pharmacological risks (eg, anticoagulation therapy and invasive cardiac catheterization) in patients with low risk for major adverse cardiac events.

### Table 1. ST-Segment Elevation or New or Presumably New LBBB: Evaluation for Reperfusion

<table>
<thead>
<tr>
<th>Step 1: Assess time and risk</th>
<th>Step 2: Select reperfusion (fibrinolysis or invasive) strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time since onset of symptoms</td>
<td>An invasive strategy is generally preferred if:</td>
</tr>
<tr>
<td>Risk of STEMI</td>
<td>• Early presentation (≤3 hours from symptom onset)</td>
</tr>
<tr>
<td>Risk of fibrinolysis</td>
<td>• Invasive strategy is not an option (eg, lack of access to skilled PCI facility or difficult vascular access) or would be delayed</td>
</tr>
<tr>
<td>Time required to transport to skilled PCI catheterization suite</td>
<td>– Medical contact-to-balloon or door-to-balloon &gt;90 minutes</td>
</tr>
<tr>
<td>Note: If presentation &lt;3 hours and no delay for PCI, then no preference for either strategy.</td>
<td>– (Door-to-balloon) minus (door-to-needle) is &gt;1 hour</td>
</tr>
<tr>
<td></td>
<td>• Contraindications to fibrinolysis</td>
</tr>
<tr>
<td></td>
<td>• High risk from STEMI (CHF, Killip class ≥3)</td>
</tr>
<tr>
<td></td>
<td>• Diagnosis of STEMI is in doubt</td>
</tr>
</tbody>
</table>

Modified from ACC/AHA 2004 Update Recommendations.®
Although the diagnosis of ACS is important and will help to guide immediate therapy, the estimation of risk for major adverse cardiac events in the immediate, short-term, and long-term time frames helps the physician determine the urgency in completing the diagnostic workup not just for ACS but also for CAD. Many patients can be managed in the outpatient setting once it is determined that they are at very low risk for short-term (30 days) major adverse cardiac events.

Braunwald Risk Stratification
ACC/AHA Guidelines recommend that all patients be risk stratified for the selection of an initial management strategy and site of care. A well-recognized approach is the one initially proposed and later refined by Braunwald and colleagues and published in ACC/AHA Guidelines on the Management of Patients With Unstable Angina and Non-ST Segment Elevation MI. This approach is based on a combination of historical, clinical, laboratory, and ECG variables and answers two questions: what is the likelihood that signs and symptoms represent ACS secondary to obstructive CAD, and what is the likelihood of an adverse clinical outcome?

Table 2 is a modified version of Braunwald and colleagues’ approach updated over several publications. Patients are initially risk-stratified according to the likelihood that symptoms are due to unstable CAD. Patients at intermediate or high risk for CAD are further classified by their risk of major adverse cardiac events. This second classification is useful for prospectively identifying patients at intermediate or high risk who can benefit from an invasive strategy and more aggressive pharmacology with antplatelet and antithrombin agents. Other risk stratification schemes include the TIMI, GRACE, and PURSUIT risk scores developed for short- and longer-term risk assessment. Stratification tools cannot be used to determine discharge from the ED.

TIMI Risk Score
The risk of major adverse cardiac events has been further studied and refined. Researchers who derived the important Thrombolysis in Myocardial Ischemia (TIMI) risk score used data from the TIMI-11B and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events) trials for UA/NSTEMI and from the In-TIME trial for STEMI.

The TIMI risk score comprises 7 independent prognostic variables (Table 3). These 7 variables were significantly associated with the occurrence within 14 days of at least one of the primary end points: death, new or recurrent MI, or need for urgent revascularization. The score is derived from complex multivariate logistic regression. It is useful to note that traditional cardiac risk factors are only weakly associated with major adverse cardiac events. Aspirin use was found to be one of the most powerful predictors. It is possible that aspirin use identified a subgroup of patients at higher risk or on active but failed therapy for CAD.

The TIMI risk score was validated with 3 groups of patients, and 4 clinical trials showed a significant interaction between the TIMI risk score and outcome (Table 3).

These findings confirm the value of the TIMI risk score as a guide to therapeutic decisions (Class IIa, LOE B).

Indicators for Early Invasive Strategies
Risk stratification (Figure 1, Boxes 9, 13, 14, 15) helps the clinician identify patients with non–ST-elevation ACS who should be managed with an early invasive strategy versus a selectively invasive one. Early coronary angiography may allow the clinician to determine whether patients are appropriate candidates for revascularization with PCI or coronary artery bypass grafting (CABG).

The 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention contains the following recommendations related to the selection of early invasive PCI versus conservative strategies.

1. An early invasive PCI strategy is indicated for patients with non–ST-elevation ACS who have no serious comorbidity and who have coronary lesions amenable to PCI and an elevated risk for clinical events (Class I, LOE A). (See Table 4 and Section 3.3 of the ACC/AHA 2007 UA/NSTEMI Guidelines).
2. An early invasive strategy (ie, diagnostic angiography with intent to perform revascularization) is indicated in non–ST-elevation ACS patients who have refractory angina or hemodynamic or electric instability (without serious comorbidities or contraindications to such procedures) (Class I, LOE B).
3. In initially stabilized patients, an initially conservative (ie, a selectively invasive) strategy may be considered as a treatment strategy for non–ST-elevation ACS patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events including those with abnormal troponin elevations (Class IIb, LOE B).
4. The decision to implement an initial conservative (versus initial invasive) strategy in these patients may be made by considering physician and patient preference (Class IIb, LOE C).

Normal or Nondiagnostic ECG Changes (Figure 1, Boxes 13 Through 17)
The majority of patients with normal or nondiagnostic ECGs do not have ACS. Patients in this category with ACS are most often at low or intermediate risk. The physician’s goal involves risk stratification (see above) to provide appropriate diagnostic or treatment strategies for an individual patient. These strategies then target patients at increased risk for benefit while avoiding risk (eg, anticoagulation therapy and invasive cardiac catheterization) in patients with low or minimal risk.

The Chest Pain Unit Model
Chest pain observation protocols may be employed in a dedicated space (ie, a physical chest pain unit [CPU]) or throughout an ED/hospital (ie, virtual CPU). These chest pain observation protocols are a rapid system of patient assessment that should generally include a history and physical examination, a period of observation, serial electrocardiography, and serial measurement of serum cardiac markers. In selected patients, an evaluation for inducible myocardial ischemia or anatomic coronary disease after MI is excluded.
when indicated. Eleven randomized trials\textsuperscript{140–150} suggest that these protocols may be used to improve accuracy in identifying patients requiring inpatient admission or further diagnostic testing and, thereby, reduce length of stay, rate of hospital admission, and health care costs while improving quality of life measures.

In patients with suspicion for ACS, normal initial biomarkers, and nonischemic ECG, chest pain observation protocols may be recommended as a safe and effective strategy for evaluating patients in the ED (Class I, LOE A). There is no direct evidence demonstrating that CPUs/observation protocols reduce adverse cardiovascular outcomes, including mortality for patients presenting with possible ACS, normal serum cardiac biomarkers, and a nondiagnostic ECG.

Advanced Testing to Detect Coronary Ischemia and CAD
For ED/CPU patients who are suspected of having ACS, have nonischemic ECG’s and negative biomarkers, a noninvasive test for inducible myocardial ischemia or anatomic evaluation of the coronary arteries (eg, computed tomography [CT] angiography, cardiac magnetic resonance, myocardial perfusion imaging, stress echocardiography) can be useful in identifying patients suitable for discharge from the ED (Class IIa, LOE B). This strategy may be considered to increase diagnostic accuracy for ACS thereby decreasing costs, length of stay, time to diagnosis, and can provide valuable short-term and long-term prognostic information of future major cardiac events.

Myocardial perfusion scintigraphy (MPS) has a high negative predictive value (NPV) for ruling out ACS; 99% in patients presenting to the ED with acute chest pain, nondiagnostic ECG, and negative cardiac markers. MPS can also be used for risk stratification, especially in low- to intermediate-likelihood of cardiac events according to traditional cardiac markers (Class IIa, LOE B).\textsuperscript{151–154} MPS is best utilized in patients with an intermediate probability or LOE of risk stratification.

The use of multidetector computed tomography (MDCT) angiography (64-slice scanner) after presentation to the ED with chest discomfort, a nondiagnostic ECG, and negative cardiac biomarkers has also been demonstrated to have high sensitivity and specificity for CAD and ACS.\textsuperscript{155,156} The use of MDCT angiography for selected low-risk patients can be useful to allow for safe early discharge from the ED (Class IIa, LOE B).\textsuperscript{157–159}

It is reasonable to consider both the exposure to radiation and iodinated contrast agents when using MDCT angiography and myocardial perfusion imaging. Little evidence is available to support the use of MRI in this patient population.

Safety of Discharge and Risk of Major Adverse Cardiac Events After Discharge From the ED/CPU
The final step in the CPU risk-stratification process is the decision to discharge or admit the patient. No simple clinical decision rule is adequate and appropriate to identify ED chest discomfort patients with suspected ACS who can be safely discharged from the ED.\textsuperscript{160} The use of inpatient-derived risk scoring systems are useful for prognosis (Class I, LOE A) but are not recommended to identify patients who may be safely discharged from the ED (Class III, LOE C).

The Bayesian process of serial assignment of pretest risk, diagnostic testing, and reclassification into post-test risk levels based on the test results is the most reliable method to identify patients at the lowest risk for short term major adverse cardiac events and those patients in need of further evaluation for underlying CAD.

Patients at low and intermediate clinical risk for ACS who have remained stable in the CPU and have negative serial ECGs, serial cardiac biomarker measurements, and noninvasive physiological or anatomic testing for ACS have very low rates of major adverse cardiac events at 30 days from ED discharge.\textsuperscript{161–165} Patients younger than 40 years-of-age with nonclassical presentations and no significant past medical history have very low short-term rates of major adverse cardiac events when serial biomarkers and 12-lead ECGs are

### Table 2. Likelihood That Signs and Symptoms Represent ACS Secondary to CAD

<table>
<thead>
<tr>
<th>Feature</th>
<th>High Likelihood Any of the following:</th>
<th>Intermediate Likelihood Absence of high-likelihood features and presence of any of the following:</th>
<th>Low Likelihood Absence of high- or intermediate-likelihood features but may have the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>Chest or left arm pain or discomfort as chief symptom reproducing prior documented angina; known history of CAD including MI</td>
<td>Chest or left arm pain or discomfort as chief symptom; age &gt;70 years; male sex; diabetes mellitus</td>
<td>Probable ischemic symptoms in absence of any intermediate-likelihood characteristics; recent cocaine use</td>
</tr>
<tr>
<td>Examination</td>
<td>Transient MR murmur, hypotension, diaphoresis, pulmonary edema, or rales</td>
<td>Extracardiac vascular disease</td>
<td>Chest discomfort reproduced by palpation</td>
</tr>
<tr>
<td>ECG</td>
<td>New or presumably new transient ST-segment deviation (≥1 mm) or T-wave inversion in multiple precordial leads</td>
<td>Fixed Q waves ST depression 0.5 to 1 mm or T-wave inversion &gt;1 mm</td>
<td>T-wave flattening or inversion &lt;1 mm in leads with dominant R waves Normal ECG</td>
</tr>
<tr>
<td>Cardiac markers</td>
<td>Elevated cardiac TnI, TnT, or CK-MB</td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>

CAD indicates coronary artery disease; CK-MB, MB fraction of creatine kinase; ECG, electrocardiogram; MI, myocardial infarction; MR, mitral regurgitation; TnI, troponin I; and TnT, troponin T.

Modified from Braunwald E, et al. Unstable Angina: Diagnosis and Management. 1994;3-1-AHCPR Publication No 94-0602:1-154. In the public domain.\textsuperscript{127}
normal. These patients may be discharged directly from the ED/CPU if appropriate outpatient testing can be arranged within 72 hours.\textsuperscript{3,161–163,165–167} Any system that attempts to facilitate outpatient testing should include mechanisms to ensure patient access to outpatient clinics and testing facilities and should consider nonmedical barriers to discharge from the ED that may require inpatient admission.

**Initial General Therapy for ACS**

Several initial therapeutic measures are appropriate for all patients with suspected ACS in the ED setting. These include continuous cardiac monitoring, establishment of intravenous (IV) access, and consideration of several medications discussed below.

**Oxygen**

Oxygen should be administered to patients with breathlessness, signs of heart failure, shock, or an arterial oxyhemoglobin saturation <94% (Class I, LOE C). Noninvasive monitoring of blood oxygen saturation can be useful to decide on the need for oxygen administration.

In the absence of compelling evidence for established benefit in uncomplicated cases, ACC/AHA Guidelines have noted that there appeared to be little justification for continuing routine oxygen use beyond 6 hours.\textsuperscript{2} There is insufficient evidence to recommend the routine usage of oxygen therapy in patients suffering from an uncomplicated AMI or an ACS without signs of hypoxemia or heart failure. Supplementary oxygen has been shown to limit ischemic myocardial injury in animals,\textsuperscript{168–171} but evidence of benefit from supplementary oxygen in patients suffering from an uncomplicated AMI or an ACS is limited.\textsuperscript{168} A case study found improvement in ST changes with the use of oxygen in humans.\textsuperscript{172} Others suggested harm with high-flow oxygen administration.\textsuperscript{173,174}

### Table 3. TIMI Risk Score for Patients With Unstable Angina and Non–ST-Segment Elevation MI: Predictor Variables

<table>
<thead>
<tr>
<th>Predictor Variable</th>
<th>Point Value of Variable</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥65 years</td>
<td>1</td>
<td>Risk factors</td>
</tr>
<tr>
<td>≥3 risk factors for CAD</td>
<td>1</td>
<td>Risk factors</td>
</tr>
<tr>
<td>Recent, severe symptoms of angina</td>
<td>1</td>
<td>≥2 anginal events in last 24 hours</td>
</tr>
<tr>
<td>Elevated cardiac markers</td>
<td>1</td>
<td>CK-MB or cardiac-specific troponin level</td>
</tr>
<tr>
<td>ST deviation ≥0.5 mm</td>
<td>1</td>
<td>ST depression &gt;0.5 mm is significant; transient ST elevation ≥0.5 mm for &lt;20 minutes is treated as ST-segment depression and is high risk; ST elevation ≥1 mm for more than 20 minutes places these patients in the STEMI treatment category</td>
</tr>
<tr>
<td>Prior coronary artery stenosis ≥50%</td>
<td>1</td>
<td>Risk predictor remains valid even if this information is unknown</td>
</tr>
</tbody>
</table>

### Calculated TIMI Risk Score

<table>
<thead>
<tr>
<th>Risk of ≥1 Primary End Point in ≤14 Days</th>
<th>Risk Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 or 1</td>
<td>Low</td>
</tr>
<tr>
<td>2</td>
<td>Low</td>
</tr>
<tr>
<td>3</td>
<td>Intermediate</td>
</tr>
<tr>
<td>4</td>
<td>Intermediate</td>
</tr>
<tr>
<td>5</td>
<td>High</td>
</tr>
</tbody>
</table>

*Primary end points: death, new or recurrent MI, or need for urgent revascularization.

**Aspirin and Nonsteroidal Anti-Inflammatory Drugs**

Early administration of aspirin (acetylsalicylic acid [ASA]), has been associated with decreased mortality rates in several clinical trials.\textsuperscript{30,32,175,176} Multiple studies support the safety of aspirin administration. Therefore, unless the patient has a known aspirin allergy or active gastrointestinal hemorrhage, nonenteric aspirin should be given as soon as possible to all patients with suspected ACS (Class I, LOE A).

Aspirin produces a rapid clinical antiplatelet effect with near-total inhibition of thromboxane A2 production. It reduces coronary reocclusion and recurrent ischemic events after fibrinolytic therapy. Aspirin alone reduced death from AMI in the Second International Study of Infarct Survival (ISIS-2), and its effect was additive to that of streptokinase.\textsuperscript{32} Aspirin was found to substantially reduce vascular events in patients with suspected ACS (Class I, LOE A).
all patients with AMI, and in high-risk patients it reduced nonfatal AMI and vascular death. Aspirin is also effective in patients with NSTEMI. The recommended dose is 160 to 325 mg. Chewable or soluble aspirin is absorbed more quickly than swallowed tablets. Aspirin suppositories (300 mg) are safe and can be considered for patients with severe nausea, vomiting, or disorders of the upper gastrointestinal tract.

Other nonsteroidal anti-inflammatory medications (NSAIDS) are contraindicated and should be discontinued in patients who are taking these medications. NSAIDs (except for aspirin), both nonselective as well as COX-2 selective agents, should not be administered during hospitalization for STEMI because of the increased risk of mortality, reinfarction, hypertension, heart failure, and myocardial rupture associated with their use (Class III, LOE C).

Nitroglycerin (or Glyceryl Trinitrate)
Nitroglycerin has beneficial hemodynamic effects, including dilation of the coronary arteries (particularly in the region of plaque disruption), the peripheral arterial bed, and venous capacitance vessels. The treatment benefits of nitroglycerin are limited, however, and no conclusive evidence has been shown to support the routine use of IV, oral, or topical nitrate therapy in patients with AMI. With this in mind, these agents should be carefully considered, especially in the patient with low blood pressure and when their use would preclude the use of other agents known to be beneficial, such as angiotensin-converting enzyme (ACE) inhibitors.

Patients with ischemic discomfort should receive up to 3 doses of sublingual or aerosol nitroglycerin at 3- to 5-minute intervals until pain is relieved or low blood pressure limits its use (Class I, LOE B). Topical nitrates are acceptable alternatives for patients who require anti-anginal therapy but who are hemodynamically stable and do not have ongoing refractory ischemic symptoms. Parenteral formulations, rather than long-acting oral preparations, can be used acutely to enable titration in patients with obvious ACS, objective test abnormality, and ongoing discomfort. In patients with recurrent ischemia, nitrates are indicated in the first 24 to 48 hours.

The use of nitrates in patients with hypotension (SBP <90 mm Hg or ≥30 mm Hg below baseline), extreme bradycardia (<50 bpm), or tachycardia in the absence of heart failure (>100 bpm) and in patients with right ventricular infarction is contraindicated (Class III, LOE C). Caution is advised in patients with known inferior wall STEMI, and a right-sided ECG should be performed to evaluate RV infarction. Administer nitrates with extreme caution, if at all, to patients with inferior-wall MI and suspected right ventricular (RV) involvement because these patients require adequate RV preload. Nitroglycerin should not be administered to patients who had taken a phosphodiesterase inhibitor (eg, sildenafil) for erectile dysfunction within 24 hours (48 hours if tadalafil use).

Relief of chest discomfort with nitroglycerin is neither sensitive nor specific for ACS; gastrointestinal etiologies as well as other causes of chest discomfort can “respond” to nitroglycerin administration.

Analgesia
Providers should administer analgesics, such as intravenous morphine, for chest discomfort unresponsive to nitrates. Morphine is the preferred analgesic for patients with STEMI (Class I, LOE C). However, analysis of retrospective registry data raised a question about the potentially adverse effects of morphine in patients with STEMI. As a result, the ACC AHA UA/NSTEMI writing group reduced morphine use to a Class IIa recommendation for that patient population.

Reperfusion Therapies (Figure 1, Box 7, 8)
Acute reperfusion therapy using PPCI or fibrinolytic therapy in patients with STEMI restores flow in the infarct-related artery, limits infarct size, and translates into early mortality benefit that is sustained over the next decade. While optimal fibrinolysis restores normal coronary flow (TIMI 3) in 50% to 60% of subjects, PPCI is able to achieve restored flow in >90% of subjects. The patency rates achieved with PPCI translates into reduced mortality and reinfarction rates as compared to fibrinolytic therapy. This benefit is even greater in patients presenting with cardiogenic shock. PPCI also results in a decreased risk of intracranial hemorrhage and stroke, making it the reperfusion strategy of choice in the elderly and those at risk for bleeding complications.

Fibrinolytics
Early fibrinolytic therapy is a well-established treatment modality for patients with STEMI who present within 12 hours of the onset of symptoms and who lack contraindications to its use. Early reperfusion results in reduced mortality, and the shorter the time to reperfusion, the greater the benefit. A 47% reduction in mortality was noted when fibrinolytic therapy was provided within the first hour after onset of symptoms.

The major determinants of myocardial salvage and long-term prognosis are short time to reperfusion, complete and sustained patency of the infarct-related artery with normal (TIMI grade 3) flow, normal microvascular perfusion, and in the absence of contraindications, fibrinolytic therapy is recommended for STEMI if symptom onset has been within 12 hours of presentation and PCI is not available within 90 minutes of first medical contact (Class I, LOE A). Patients are evaluated for risk and benefit; for absolute and relative contraindications to therapy (see Table 5).

If fibrinolysis is chosen for reperfusion, the ED physician should administer fibrinolytics to eligible patients as early as possible according to a predetermined process of care developed by the ED and cardiology staff (Class I, LOE A). The goal is a door-to-needle time of less than 30 minutes with effort focused on shortening the time to therapy. Patients treated within the first 70 minutes of onset of symptoms have >50% reduction in infarct size and 75% reduction in mortality rates. For fibrinolytic therapy, it is estimated that 65 lives will be saved per 1000 patients treated if fibrinolytics are provided in the first hour, with a pooled total of 131 lives saved per 1000 patients treated if fibrinolytics are provided within the first 3 hours of onset of symptoms. Although fibrinolytics may be beneficial if given within 12 hours after...
Table 5. Fibrinolytic Therapy

<table>
<thead>
<tr>
<th>Contraindications and cautions for fibrinolytic use in STEMI from ACC/AHA 2004 Guideline Update*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absolute Contraindications</strong></td>
</tr>
<tr>
<td>• Any prior intracranial hemorrhage</td>
</tr>
<tr>
<td>• Known structural cerebral vascular lesion (eg, AVM)</td>
</tr>
<tr>
<td>• Known malignant intracranial neoplasm (primary or metastatic)</td>
</tr>
<tr>
<td>• Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours</td>
</tr>
<tr>
<td>• Suspected aortic dissection</td>
</tr>
<tr>
<td>• Active bleeding or bleeding diathesis (excluding menses)</td>
</tr>
<tr>
<td>• Significant closed head trauma or facial trauma within 3 months</td>
</tr>
<tr>
<td><strong>Relative Contraindications</strong></td>
</tr>
<tr>
<td>• History of chronic, severe, poorly controlled hypertension</td>
</tr>
<tr>
<td>• Severe uncontrolled hypertension on presentation (SBP &gt;180 mm Hg or DBP &gt;110 mm Hg)†</td>
</tr>
<tr>
<td>• History of prior ischemic stroke &gt;3 months, dementia, or known intracranial pathology not covered in contraindications</td>
</tr>
<tr>
<td>• Traumatic or prolonged (&gt;10 minutes) CPR or major surgery (&lt;3 weeks)</td>
</tr>
<tr>
<td>• Recent (within 2 to 4 weeks) internal bleeding</td>
</tr>
<tr>
<td>• Noncompressible vascular punctures</td>
</tr>
<tr>
<td>• For streptokinase/anistreplase: prior exposure (&gt;5 days ago) or prior allergic reaction to these agents</td>
</tr>
<tr>
<td>• Pregnancy</td>
</tr>
<tr>
<td>• Active peptic ulcer</td>
</tr>
<tr>
<td>• Current use of anticoagulants: the higher the INR, the higher the risk of bleeding</td>
</tr>
</tbody>
</table>

CPR, cardiopulmonary resuscitation; AVM indicates arteriovenous malformation; SBP, systolic blood pressure; DBP, diastolic blood pressure; INR, International Normalized Ratio.
*Viewed as advisory for clinical decision making and may not be all-inclusive or definitive.
†Could be an absolute contraindication in low-risk patients with myocardial infarction.

onset of symptoms, the mortality benefit is time sensitive, with shorter intervals to administration being associated with better outcomes.201,202

Patients with STEMI presenting at later times in the myocardial infarction evolution are much less likely to benefit from fibrinolysis. In fact, fibrinolytic therapy is generally not recommended for patients presenting between 12 and 24 hours after onset of symptoms based on the results of the LATE and EMERAS trials.201,204 unless continuing ischemic pain is present with continuing ST-segment elevation (Class IIb, LOE B). Fibrinolytic therapy should not be administered (Class III, LOE B) to patients who present greater than 24 hours after the onset of symptoms.

**Risks of Fibrinolytic Therapy**

Physicians who administer fibrinolytic agents must be aware of the indications, contraindications, benefits, and major risks of administration so that they are able to weigh the net clinical benefit for each patient (see Table 5).203,204 This net clinical benefit requires integration of relative and absolute contraindications versus overall potential clinical gain.

Patients who present early after symptom onset with extensive ECG changes (consistent with a large AMI) and a low risk of intracranial bleeding receive the greatest benefit from fibrinolytic therapy.190 Patients who have symptoms highly suggestive of ACS and ECG findings consistent with LBBB are also appropriate candidates for intervention because they have the highest mortality rate when LBBB is due to extensive AMI. Inferior wall STEMI also benefits from fibrinolysis, yet the magnitude of this outcome improvement is markedly less robust. More extensive inferior STEMI presentations, of course, demonstrate more robust benefit when undergoing fibrinolysis; inferior wall STEMI with RV involvement is such an example. Fibrinolytics have been shown to be beneficial across a spectrum of patient subgroups with comorbidities such as previous MI, diabetes, tachycardia, and hypotension.190 Although superior to placebo, the lack of efficacy in the setting of cardiogenic shock makes referral for PPCI an optimal strategy in this setting.

Although older patients (>75 years) have a higher risk of death, their absolute benefit appears to be similar to that of younger patients. The incidence of stroke does increase with advancing age,205,206 reducing the relative benefit of fibrinolytic therapy. Older age is the most important baseline variable predicting nonhemorrhagic stroke.206 Although 1 large trial reported lower early and 1-year mortality rates with accelerated administration of tissue plasminogen activator (rtPA) in patients <85 years of age,207 a retrospective analysis found no specific survival advantage and possible risk for patients >75 years of age.208

**Intracranial Hemorrhage**

Fibrinolytic therapy is associated with a small but definite increase in the risk of hemorrhagic stroke, which contributes to increased mortality.190 More intensive fibrinolytic regimens using rtPA (alteplase) and heparin pose a greater risk than streptokinase and aspirin.200,209 Clinical factors that may help risk-stratify patients at the time of presentation are age (≥65 years), low body weight (<70 kg), hypertension on presentation (>180/110 mm Hg), and use of rtPA. The number of risk factors can be used to estimate the frequency of stroke, which ranges from 0.25% with no risk factors to 2.5% with 3 risk factors.204 Several risk factor estimates are available for use by clinicians, including Simoons,204 the Co-Operative Cardiovascular Project,210 and the In-Time 2 trial.211

**Percutaneous Coronary Intervention (PCI)**

Coronary angioplasty with or without stent placement is the treatment of choice for the management of STEMI when it can be performed effectively with a door-to-balloon time <90 minutes by a skilled provider (performing >75 PCIs per year) at a skilled PCI facility (performing >200 PCIs annually, of which at least 36 are primary PCI for STEMI) (Class I, LOE A).2,212,213 PPCI may also be offered to patients presenting to non-PCI centers when prompt transfer can result in an effective balloon time of <90 minutes from first medical contact as a systems goal.214 The TRANSFER AMI trial supports the transfer of high-risk patients who receive fibrinolysis in a non-PCI center to a PCI center within 6 hours of presentation to receive routine early PCI.215
PCI Following ROSC After Cardiac Arrest

Each year in the United States, 236,000 to 325,000 patients experience out-of-hospital cardiac arrest, and the prognosis is generally grim with a median survival to discharge rate of only 8.4%. Large variations in outcome have been observed across EMS systems, and this has resulted in a call for regionalization of care with a goal to optimize the utilization of proven beneficial therapies and interventions. Despite the lack of data from RCTs in this situation, the performance of PCI has been associated with favorable outcomes in this setting and is supported by the observation that following early angiography, half of the studied population is noted to have an acute coronary occlusion. The data are strongest for patients with out-of-hospital cardiac arrest due to VF in the setting of STEMI (or new or presumably new LBBB), and emergent angiography with prompt recanalization of the infarct-related artery is recommended (Class I, LOE B). PPCI also appears applicable in the setting of NSTEMI subjects in whom emergent revascularization may result in hemodynamic and electric stability. PPCI after ROSC in subjects with arrest of presumed ischemic cardiac etiology may be reasonable, even in the absence of a clearly defined STEMI (Class IIb, LOE B).

There is concern that the poor prognosis for out-of-hospital cardiac arrest will prove detrimental to the public perception and reputation of interventional programs dedicated to treating patients following ROSC because of poorer outcome that could adversely affect mortality data for PCI programs. As a result, the AHA policy statement strongly supports a mechanism to report PCI outcomes for out-of-hospital cardiac arrest separate from PCI outcomes following STEMI, as this will remove potential barriers for interventional cardiologists to actively participate in the care of this population. In contrast to PCI, randomized control trials of acute reperfusion therapy using fibrinolytic agents have been performed in subjects with out-of-hospital cardiac arrest without a favorable outcome.

A 12-lead ECG should be performed as soon as possible after ROSC. Clinical findings of coma in patients prior to PCI are commonly present in patients with out-of-hospital cardiac arrest, and should not be a contraindication to consider immediate angiography and PCI. It is reasonable to include cardiac catheterization and coronary angiography in standardized post–cardiac arrest protocols as part of an overall strategy to improve neurologically intact survival in this patient group (Class IIa, LOE B) and appropriate treatment of ACS or STEMI, including PCI or fibrinolysis, should be initiated regardless of coma (Class I, LOE B). Angiography and/or PCI need not preclude or delay other therapeutic strategies including therapeutic hypothermia (Class IIa, LOE B).

Cardiac angiography and PCI, when used as part of a standardized advanced post–cardiac arrest protocol, may result in improved survival to hospital discharge. Acute coronary artery occlusion is frequent in survivors of out-of-hospital cardiac arrest. PCI is feasible following ROSC, and almost 50% of cardiac arrest survivors have an acute thrombotic occlusion, or culprit lesion, that is amenable to reperfusion. In addition, successful PCI can result in improved cardiac ejection fraction and survival. Cardiac catheterization alone (without PCI) has been associated with improved neurologically intact survival. Although coronary artery occlusion after cardiac arrest is associated with ST elevation or LBBB, specific ECG findings may also be conspicuously absent.

Outcomes after angiography and PCI vary considerably depending on patient subsets. Survival in post–cardiac arrest patients with STEMI is as high as 70% to almost 100% with shorter durations of witnessed arrest due to VF. A significant number of eventual survivors may initially be comatose before PCI.

A 12-lead ECG should be performed as soon as possible after ROSC (Class I, LOE A). Appropriate treatment of ACS or STEMI, including PCI or fibrinolysis, should be initiated regardless of coma (Class I, LOE B). Coma and the use of induced hypothermia are not contraindications or reasons to delay PCI or fibrinolysis.

PCI Versus Fibrinolytic Therapy

For patients admitted to hospitals with PCI facilities, PPCI confers clinical benefit as compared to fibrinolysis (both in terms of death and reinfarction or stroke) for the majority of patients. There is scant evidence for incremental benefit of PCI over fibrinolysis for specific subgroups such as post-CABG patients or patients with renal failure.

PCI is the preferred reperfusion strategy in the STEMI patient who can arrive in the catheterization laboratory with balloon inflation within 90 minutes of initial hospital arrival. As a system goal, PCI should ideally be performed within 90 minutes of first medical contact. PCI should be performed by an experienced provider (an individual who performs >75 PCI procedures per year) in a high-volume center (a laboratory that performs more than 200 PCI procedures per year, of which at least 36 are PCI for STEMI). High-risk STEMI patients, “late presenters” (ie, >3 hours since the onset of STEMI symptoms), and individuals with contraindication to fibrinolysis are all candidates for PCI as well. And, of course, if the diagnosis of STEMI is in doubt, regardless of the reason, initial coronary angiography followed by PCI is the most appropriate diagnostic and therapeutic strategy.

Although PCI may offer an improved outcome over fibrinolysis, catheter-based techniques must be applied early without prolonged delay. If applied without delay by experienced providers, PCI provides improved outcome in the STEMI patient. As noted in the DANAMI-2 study, PCI initiated within 3 hours of initial hospital arrival was superior to fibrinolysis. For patients admitted in hospital without PCI capabilities, there may be some benefit associated with transferring patients for PPCI versus on-site fibrinolitics in terms of reinfarction, stroke and a trend to a lower mortality in the PPCI group. For patients with cardiogenic shock, early revascularization was associated with improved survival at six months, especially in patients younger than 75 years-of-age. Transfer for PCI instead of more immediate fibrinolysis has shown the combined rate of death, nonfatal MI, and stroke to be reduced by 42% if the mean transfer to PCI time could be less than 80 to 122 minutes.
If the time required to mobilize staff and arrange for PCI is prolonged or delays in transfer are anticipated, the treating physician must consider fibrinolysis, assuming that the patient is an appropriate candidate. Time delays to PCI range from 45 to 120 minutes and are associated with age, symptom duration, and location of infarction. These delays may negate the benefit of PCI over fibrinolysis. In addition, the benefit of PCI over fibrinolysis is offset when PCI is carried out in low-volume PCI centers. PCI has been shown to be superior to fibrinolysis on the combined end points of short-term death, nonfatal myocardial infarction, and stroke.

Pinto and colleagues have performed a very important analysis of the “PCI versus fibrinolysis” consideration in the STEMI patient. Their analysis asked the following questions for the patient with STEMI: How long should the practitioner wait for PCI in a patient who is fibrinolytic eligible? And, in this waiting period for PCI, when is the benefit of the catheter-based therapy lost and fibrinolysis becomes the preferred option? Time recommendations—essentially the answer to the above questions—are provided with respect to patient age, infarct duration, and MI anatomic location. This paper provides the emergency physician with the total elapsed time that he or she should wait for PCI, at which point the survival benefit of the invasive strategy is lost and the patient should receive a fibrinolytic agent. These times include the following:

- For patients presenting within 2 hours of symptom onset: 94 minutes
- For patients presenting beyond 2 hours of symptom onset: 190 minutes
- For patients less than 65 years of age: 71 minutes
- For patients greater than 65 years of age: 155 minutes
- Anterior STEMI: 115 minutes
- Nonanterior STEMI: 112 minutes

Further analysis combined commonly encountered clinical variables in typical STEMI presentations:

- Patient presentation within 2 hours of symptom onset and
  - anterior STEMI with age <65 years: 40 minutes
  - anterior STEMI with age ≥65 years: 107 minutes
  - non-anterior STEMI with age <65 years: 58 minutes
  - non-anterior STEMI with age ≥65 years: 168 minutes
- Patient presentation beyond 2 hours of symptom onset and
  - anterior STEMI with age <65 years: 43 minutes
  - anterior STEMI with age ≥65 years: 148 minutes
  - nonanterior STEMI with age <65 years: 103 minutes
  - nonanterior STEMI with age ≥65 years: 179 minutes

Post hoc analysis and theoretical constructs have addressed the time delay that mitigates the benefit of PPCI as compared to fibrinolytic therapy in the absence of randomized trials. The time delay has been analyzed to be between 60 and 120 minutes. Taking these into consideration, the recent European Society of Cardiology recommendation extended the time delay indicating that PPCI should be performed within 2 hours from first medical contact except in those patients with a large amount of myocardium at risk (maximum delay of 90 minutes). The ACC AHA 2009 Focused STEMI Writing Group noted, “There has been discussion about whether the recommended door-to-balloon time (or first medical contact to balloon time) should be greater than 90 minutes. However, the writing group continues to believe that the focus should be on developing systems of care to increase the number of patients with timely access to PCI rather than extending the acceptable window for door-to-balloon time.”

Delays to reperfusion therapy are not without negative consequence as noted in a subset of patients in the GRACE (Global Registry of Acute Coronary Events) database. The authors of this registry examined the outcome impact of treatment delays on STEMI patients receiving reperfusion therapy. This study involved 3959 patients from 106 hospitals in 14 countries who presented within 6 hours of chest pain onset and underwent either PCI (55%) or fibrinolysis (45%). Delays in reperfusion were associated with increased mortality for both treatment strategies, yet were more pronounced in those patients receiving fibrinolysis.

A cooperative and interdisciplinary effort between emergency medicine and cardiology, as well as among the EMS agencies, the catheterization laboratory, and the CCU, has the potential to reduce markedly the door-to-therapy time in STEMI patients and therefore limit delays in providing this time-sensitive treatment. Prior agreement between the ED and cardiovascular physicians at institutions with invasive capability must be obtained so that consideration of PCI does not introduce further delays in fibrinolytic drug administration; such cooperation can limit additional delays in the administration of fibrinolytic agents in patients who are considered for PCI in AMI.

A systems of care approach involving a reperfusion team or “STEMI alert” system mobilizes hospital-based resources, optimizing the approach to the patient. This system, whether activated by data gathered in the ED orprehospital-based information, has the potential to offer time-sensitive therapies in a rapid fashion to these ill patients.

In summary, for patients presenting within 12 hours of symptom onset and electrocardiographic findings consistent with STEMI, reperfusion should be initiated as soon as possible – independent of the method chosen (Class I, LOE A). Primary PCI performed at a high-volume center within 90 minutes of first medical contact by an experienced operator that maintains an appropriate expert status is reasonable, as it improves morbidity and mortality as compared with immediate fibrinolysis (<30 minutes door-to-needle) (Class I, LOE A). If PCI cannot be accomplished within 90 minutes of first medical contact, independent of the need for emergent transfer, then fibrinolysis is recommended, assuming the patient lacks contraindications to such therapy (Class I, LOE B). For those patients with a contraindication to fibrinolysis, PCI is recommended despite the delay, rather than foregoing reperfusion therapy (Class I, LOE A). For those STEMI patients presenting in shock, PCI (or CABG) is the preferred reperfusion treatment. Fibrinolysis should only be consid-
ered in consultation with the cardiologist if there is a substantial delay to PCI.

**Complicated AMI**

**Cardiogenic Shock, LV Failure, and Congestive Heart Failure**

Infarction of ≥40% of the LV myocardium usually results in cardiogenic shock and carries a high mortality rate. Of those who developed shock,244 patients with ST-segment elevation developed shock significantly earlier than patients without ST-segment elevation. Cardiogenic shock and congestive heart failure are not contraindications to fibrinolysis, but PCI is preferred if the patient is at a facility with PCI capabilities. Based on the results of the SHOCK trial ACC/AHA guidelines note that PCI is reasonable in those who develop shock within 36 hours of symptom onset and who are suitable candidates for revascularization that can be performed within 18 hours of the onset of shock.3 Although the benefits in the SHOCK trial were observed only in patients ≥75 years of age, selected elderly patients also appear to benefit from this strategy. The guidelines also support the use of hemodynamic support with intra-aortic balloon counterpulsation (IABP) in this setting as part of aggressive medical treatment. The IABP works synergistically with fibrinolytic agents in this setting, and the benefits observed with early revascularization strategy in the SHOCK trial were also obtained in the setting of IABP support. The use of PPCI for patients with cardiogenic shock has increased over time and contributes to the observed decrease in hospital mortality.247–249 In hospitals without PCI facilities, emergency PCI-capable center.3

**Adjunctive Therapies for ACS and AMI**

**Thienopyridines**

**Clopidogrel**

Clopidogrel is an oral thienopyridine prodrug that irreversibly inhibits the adenosine diphosphate receptor on the platelet, resulting in a reduction in platelet aggregation through a different mechanism than aspirin. Since the publication of the 2005 AHA Guidelines, several important clopidogrel studies have been published that document its efficacy for patients with both NSTEMI and STEMI.

There is a reduction in combined event rate (cardiovascular mortality, nonfatal infarction, and nonfatal stroke) and/or mortality; with a resultant small increase in major bleeding when clopidogrel is administered by providers in the ED or in hospital to patients with NSTEMI ACS.254–256 Patients with ACS and a rise in cardiac biomarkers or ECG changes consistent with ischemia had reduced stroke and major adverse cardiac events if clopidogrel was added to aspirin and heparin within 4 hours of hospital presentation.257 Clopidogrel given 6 hours or more before elective PCI for patients with ACS without ST elevation reduces adverse ischemic events at 28 days.258

The Clopidogrel in Unstable angina to prevent Recurrent Ischemic Events (CURE) trial documented an increased rate of bleeding (but not intracranial hemorrhage) in the 2072 patients undergoing CABG within 5 to 7 days of administration.259 Although a posthoc analysis of this trial reported a trend toward life-threatening bleeding257 and a prospective study failed to show increased bleeding in 1366 patients undergoing CABG,260 a subsequent risk-to-benefit ratio analysis concluded that the bleeding risk with clopidogrel in patients undergoing CABG was modest. The use of clopidogrel in ACS patients with a high likelihood of needing CABG requires weighing the risk of bleeding if given against the potential for perioperative ACS events if withheld. The current ACC/AHA guidelines recommend withholding clopidogrel for 5 to 7 days in patients for whom CABG is anticipated.

In patients up to 75 years of age with STEMI managed by fibrinolysis, a consistent improvement in combined event rate (cardiovascular mortality, nonfatal infarction, and nonfatal stroke) and/or mortality, with a resultant small increase in major bleeding, is observed when clopidogrel, in a 300-mg loading dose, was administered in addition to aspirin and heparin (low-molecular-weight heparin [LMWH] or unfractionated heparin [UFH]), at the time of initial management (followed by a 75 mg daily dose for up to 8 days in hospital).260–265

In patients with STEMI managed with PPCI, there is a reduction in combined event rate (cardiovascular mortality, nonfatal infarction, and nonfatal stroke) and/or mortality with a resultant small increase in major bleeding.
when clopidogrel is administered by ED, hospital, or prehospital providers.261,264–267

On the basis of these findings, providers should administer a loading dose of clopidogrel in addition to standard care (aspirin, anticoagulants, and reperfusion) for patients determined to have moderate- to high-risk non-ST-segment elevation ACS and STEMI (Class I, LOE A).257 In patients <75 years of age a loading dose of clopidogrel 300 to 600 mg with non-ST ACS and STEMI, regardless of approach to management, is recommended. It is reasonable to administer a 300-mg oral dose of clopidogrel to ED patients with suspected ACS (without ECG or cardiac marker changes) who are unable to take aspirin because of hypersensitivity or major gastrointestinal intolerance (Class Ila, LOE B). Providers should administer a 300-mg oral dose of clopidogrel to ED patients up to 75 years of age with STEMI who receive aspirin, heparin, and fibrinolysis (Class I, LOE B). There is little evidence on the use of a loading dose of clopidogrel in patients aged ≥75 years of age with NSTEMI and STEMI treated by PCI, and patients >75 years of age were excluded in the studies on STEMI treated by fibrinolysis, therefore the ideal dose of clopidogrel in patients over 75 years of age has yet to be delineated. In the ED the choice of immediate antiplatelet therapy (as well as protocols for STEMI and NSTEMI) should be guided by local interdisciplinary review of ongoing clinical trials, guidelines, and recommendations.

Prasugrel
Prasugrel is an oral thienopyridine prodrug that irreversibly binds to the ADP receptor to inhibit platelet aggregation. Prasugrel may be associated with a reduction in combined event rate (cardiovascular mortality, nonfatal infarction, and nonfatal stroke) with no benefit in mortality compared to clopidogrel but with an overall resultant increase in major bleeding (as compared to clopidogrel) when administered after angiography to patients with NSTEMI and STEMI treated by PCI.268–272 Risk factors associated with a higher rate of bleeding with prasugrel use are age ≥75 years, previous stroke or TIA, and body weight less than 60 kg. Small improvements in combined event rate (cardiovascular mortality, nonfatal infarction, and nonfatal stroke) and/or mortality are observed when prasugrel (compared to clopidogrel) is administered before or after angiography to patients with NSTEMI and STEMI managed with PCI.268–271,273,274 Prasugrel (60 mg oral loading dose) may be substituted for clopidogrel after angiography in patients determined to have non-ST-segment elevation ACS or STEMI who are more than 12 hours after symptom onset prior to planned PCI (Class Ila, LOE B). There is no direct evidence for the use of prasugrel in the ED or prehospital settings. In patients who are not at high risk for bleeding, administration of prasugrel (60-mg oral loading dose) prior to angiography in patients determined to have STEMI ≤12 hours after the initial symptoms may be substituted for administration of clopidogrel (Class Ila, LOE B). Prasugrel is not recommended in STEMI patients managed with fibrinolysis or NSTEMI patients before angiography.

Glycoprotein IIb/IIIa Inhibitors
The use and efficacy of glycoprotein IIb/IIIa receptor inhibitors for treatment of patients with UA/NSTEMI has been well established.274–279 These trials were conducted prior to contemporary conservative and invasive strategies, and ongoing questions have been investigated concerning their timing (eg, upstream initiation) and use combined with other contemporary agents (eg, clopidogrel).

Two recent studies do not support the routine use of upstream GP IIb/IIIa inhibitors.280,281 Other studies have documented benefit largely in patients who have elevated cardiac troponin and a planned invasive strategy or specific subsets such as those patients with diabetes or significant ST-segment depression on the presenting ECG.282–286 The current evidence supports a selective strategy for the use of GP IIb/IIIa inhibitors in the use of dual platelet inhibitor treatment of patients with planned invasive strategy taking into consideration the ACS risk of the patient and weighing this against the potential bleeding risk. There is no current evidence supporting the routine use of GP IIb/IIIa inhibitor therapy prior to angiography in patients with STEMI and use of these agents upstream is uncertain. Use of GP IIb/IIIa inhibitors should be guided by local interdisciplinary review of ongoing clinical trials, guidelines, and recommendations.

β-Adrenergic Receptor Blockers
Controversy surrounds the administration of β-adrenergic receptor blockers in the setting of ACS. Several studies have shown reduced mortality297,288 and decreased infarct size289–291 with early IV β-blocker use. Early β-blocker administration may help prevent dangerous arrhythmias288,290,292,293 and reduce reinfarction, but there is an increased incidence of cardiogenic shock.

Recent evidence shows no particular benefit to the IV administration of β-blockers on either mortality, infarct size, prevention of arrhythmias, or reinfarction294–301 There may be, however, a statistically significant short-term benefit to 6-week mortality when IV β-blockers were given to low-risk (ie, Killip Class I) patients.294,295 IV β-blockers may also be beneficial for NSTEMI. One study302 suggested that the earlier the IV β-blockers were administered, the greater the effect seen on infarct size and mortality. Of note, none of the papers reviewed showed that β-blockers caused irreversible harm when given early in the development of suspected ACS. Balancing the evidence overall for non-ST-segment elevation ACS patients, current ACC/AHA Guidelines recommend β-blockers be initiated orally within the first 24 hours after hospitalization.3

Contraindications to β-blockers are moderate to severe LV failure and pulmonary edema, bradycardia (<60 bpm), hypotension (SBP <100 mm Hg), signs of poor peripheral perfusion, second-degree or third-degree heart block, or reactive airway disease. Studies of β-blockers varied significantly in the treatment times used, with no high quality papers studying the administration of β-blockers in the prehospital setting or in the very early ED setting (ie, within the first hour of a suspected ACS).

For patients with ACS, there is no evidence to support the routine administration of IV β-blockers in the prehos-
pital setting or during initial assessment in the ED. IV beta-blocker therapy may be considered as reasonable in specific situations such as severe hypertension or tachyarrhythmias in patients without contraindications (Class IIa, LOE B). In the absence of contraindications, PO beta-blockers should be administered within the first 24 hours to patients with suspected ACS (Class 1, LOE A). Patients with initial contraindications should be re-evaluated periodically. It is reasonable to start oral beta-blockers with low doses after the patient is stabilized prior to discharge (Class IIa, LOE B).

**Heparins**

Heparin is an indirect inhibitor of thrombin that has been widely used in ACS as adjunctive therapy for fibrinolysis and in combination with aspirin and other platelet inhibitors for the treatment of non-ST-segment elevation ACS. UFH has several disadvantages, including (1) the need for IV administration; (2) the requirement for frequent monitoring of the activated partial thromboplastin time (aPTT); (3) an unpredictable anticoagulant response in individual patients; and (4) heparin can also stimulate platelet activation, causing thrombocytopenia. Because of the limitations of heparin, newer preparations of LMWH have been developed.

**Unfractionated Heparin Versus Low-Molecular-Weight Heparin in UA/NSTEMI**

**Enoxaparin**

Eleven in-hospital randomized clinical trials, and additional studies (including 7 meta-analyses) document similar or improved composite outcomes (death, MI, and/or recurrent angina or recurrent ischemia or revascularization) when enoxaparin was administered instead of UFH to patients with non-ST-segment elevation ACS with an increase in the proportion of patients with minor bleeding complications.

**Fondaparinux**

There was similar or improved outcomes of combined end points (death, MI, urgent revascularization) without increased bleeding when fondaparinux was administered in-hospital rather than UFH in patients with non-ST-segment elevation ACS. Fondaparinux was associated with increased risk of catheter thrombosis in PCI.

**Bivalirudin**

No benefit in combined outcome was observed when bivalirudin was administered in hospital compared to UFH in patients with non-ST-segment elevation ACS, however less bleeding was observed with bivalirudin and no renal dosing is required.

**Treatment Recommendations for UA/NSTEMI**

For in-hospital patients with NSTEMI managed with a planned initial conservative approach, either fondaparinux (Class IIa, LOE B) or enoxaparin (Class IIa, LOE A) are reasonable alternatives to UFH or placebo. For in-hospital patients with NSTEMI managed with a planned invasive approach, either enoxaparin or UFH are reasonable choices (Class IIa, LOE A). Fondaparinux may be used in the setting of PCI, but requires co-administration of UFH and does not appear to offer an advantage over UFH alone (Class IIb, LOE A). For in-hospital patients with NSTEMI and renal insufficiency, bivalirudin or UFH may be considered (Class IIb, LOE A). For in-hospital patients with NSTEMI and increased bleeding risk, where anticoagulant therapy is not contraindicated, fondaparinux (Class IIa, LOE B) or bivalirudin (Class IIa, LOE A) are reasonable and UFH may be considered (Class IIb, LOE C). There is no specific evidence for or against anticoagulant use in NSTEMI in the prehospital setting.

**Unfractionated Heparin Versus Low-Molecular-Weight Heparin With Fibrinolysis in STEMI**

Nine randomized clinical trials and additional studies (including one meta-analysis) document similar or improved composite outcomes (death, MI, and/or recurrent angina or recurrent ischemia or revascularization) when enoxaparin was administered instead of UFH to patients with STEMI undergoing fibrinolysis. This must be balanced against an increase in intracranial hemorrhage in patients >75 years of age who received enoxaparin documented in one of these randomized controlled trials.

One randomized clinical trial demonstrated superiority in clinical outcomes when fondaparinux was compared to UFH in patients treated with fibrinolysis.

**Enoxaparin**

For patients with STEMI managed with fibrinolysis in the hospital, it is reasonable to administer enoxaparin instead of UFH (Class IIa, LOE A). In addition, for prehospital patients with STEMI managed with fibrinolysis, adjunctive enoxaparin instead of UFH may be considered (Class IIb, LOE A). Patients initially treated with enoxaparin should not be switched to UFH and vice versa because of increased risk of bleeding (Class III, LOE C). In younger patients <75 years the initial dose of enoxaparin is 30 mg IV bolus followed by 1 mg/kg SC every 12 hours (first SC dose shortly after the IV bolus) (Class IIb, LOE A). Patients ≥75 years may be treated with 0.75 mg/kg SC enoxaparin every 12 hours without an initial IV bolus (Class IIb, LOE B). Patients with impaired renal function (creatinine clearance <30 mL/min) may be given 1 mg/kg enoxaparin SC once daily (Class IIb, LOE B). Patients with known impaired renal function may alternatively be managed with UFH (Class IIb, LOE B).

**Fondaparinux**

Fondaparinux (initially 2.5 mg IV followed by 2.5 mg SC once daily) may be considered in the hospital for patients treated specifically with non-fibrin-specific thrombolytics (ie, streptokinase), provided the creatinine is <3 mg/dL (Class IIb, LOE B).

There are insufficient data to recommend other LMWH or bivalirudin over UFH in patients treated with fibrinolysis in STEMI.
Unfractionated Heparin Versus Low-Molecular-Weight Heparin With PPCI in STEMI

Two registry studies\textsuperscript{342,343} and other studies demonstrated similar or improved outcomes when enoxaparin was compared to UFH in patients undergoing PPCI combined with a GP IIb/IIIa antagonist and thienopyridine inhibitor.

One large clinical trial\textsuperscript{340} demonstrated better outcomes in terms of acute cardiac events and bleeding using fondaparinux and PPCI. Thrombus formation on catheter material in patients on fondaparinux, however, required the addition of UFH during PCI.\textsuperscript{324}

Two large randomized clinical trials resulted in less bleeding and a short- and long-term reduction in cardiac events and overall mortality with bivalirudin compared to UFH plus a glycoprotein inhibitor in patients with STEMI and PPCI.\textsuperscript{344,345}

For patients with STEMI undergoing contemporary PCI (ie, additional broad use of glycoprotein IIb/IIIa inhibitors and a thienopyridine) enoxaparin may be considered a safe and effective alternative to UFH (Class IIb, LOE B). Patients initially treated with enoxaparin should not be switched to UFH and vice versa to avoid increased risk of bleeding. Fondaparinux may be considered as an alternative to UFH, however, there is an increased risk of catheter thrombi with fondaparinux alone. Additional UFH (50 to 100 U/kg bolus) may help to avoid this complication (Class IIb, LOE B), but using these two agents is not recommended over UFH alone. For fondaparinux and enoxaparin it is necessary to adjust the dose in patients with renal impairment. Bivalirudin may be considered as an alternative to UFH and GP IIb/IIIa inhibitors (Class IIb, LOE A).

Calcium Channel Blockers

There is little evidence that calcium channel blocking agents can be safely used as an alternative or additional therapy to β-blockers when the later are contraindicated or their maximum dose has been achieved.

Calcium channel blocking agents have not been shown to reduce mortality after acute MI, and in certain patients with cardiovascular disease there are data to suggest that they are harmful. β-blockers have been used much more broadly, have a much safer profile, and appear to be a more appropriate choice for patients presenting with myocardial infarction compared to calcium channel blockers.

ACE Inhibitor Therapy

ACE Inhibitors and ARBs in the Hospital

ACE inhibitor therapy has improved survival rates in patients with AMI, particularly when started early after the initial hospitalization.\textsuperscript{183,346–349} Evidence from 7 large clinical trials,\textsuperscript{183,346–351} 2 meta-analyses,\textsuperscript{352,353} and 10 minor trials\textsuperscript{346,351,354–362} documents consistent improvement in mortality when oral ACE inhibitors are administered in the hospital setting to patients with AMI with or without early reperfusion therapy. In these studies ACE inhibitors were not administered in the presence of hypotension (SBP <100 mm Hg or ≥30 mm Hg below baseline). The beneficial effects are most pronounced in patients with anterior infarction, pulmonary congestion, or LV ejection fraction <40%.

Administration of an oral ACE inhibitor is recommended within the first 24 hours after onset of symptoms in STEMI patients with pulmonary congestion or LV ejection fraction <40%, in the absence of hypotension (SBP <100 mm Hg or ≥30 mm Hg below baseline) (Class I, LOE A). Oral ACE inhibitor therapy can also be useful for all other patients with AMI with or without early reperfusion therapy (Class IIa, LOE B). IV administration of ACE inhibitors is contraindicated in the first 24 hours because of risk of hypotension (Class III, LOE C).

ACE Inhibitors in the Prehospital Setting

Despite multiple studies that have shown a benefit of ACE inhibitors and ARBs in patients with a myocardial infarction when therapy is started during the first 24 hours of the index hospitalization, no trial specifically evaluates patients in the ED or prehospital settings. An older randomized trial showed a reduction in mortality with an increased risk of hypotension in patients treated soon after presentation in the inpatient setting.\textsuperscript{183} Several trials showed a reduction in the rate of heart failure and mortality in patients treated soon after fibrinolysis,\textsuperscript{363–365} and several others showed no benefit with the early or prehospital use of angiotensin converting enzyme.\textsuperscript{364,366,367}

In conclusion, although ACE inhibitors and ARBs have been shown to reduce long-term risk of mortality in patients suffering an AMI, there is insufficient evidence to support the routine initiation of ACE inhibitors and ARBs in the prehospital or ED setting (Class IIb, LOE C).

HMG Coenzyme A Reductase Inhibitors (Statins)

A variety of studies documented consistent reduction in indicators of inflammation and complications such as reinfarction, recurrent angina, and arrhythmias when statin treatment is administered within a few days after onset of an ACS.\textsuperscript{368–371} There is little data to suggest that this therapy should be initiated within the ED; however, early initiation (within 24 hours of presentation) of statin therapy is recommended in patients with an ACS or AMI (Class I, LOE C). If patients are already on statin therapy, continue the therapy (Class IIb, LOE C).

An increase in short-term mortality and incidence of major adverse cardiac events have been reported with discontinuation of statin treatment in ACS patients at hospital admission. Statins should not be discontinued during the index hospitalization unless contraindicated (Class III, LOE C).\textsuperscript{372–381}

Pretreatment with statins in patients undergoing elective percutaneous angioplasty for stable angina or hemodynamically stable ACS has been shown to significantly reduce biomarkers of myocardial necrosis or inflammation compared to placebo when given between 3 and 7 days prior to the procedure.\textsuperscript{382,383}

Furthermore, pretreatment with atorvastatin 80 mg 12 hours before and an additional 40 mg immediately before PCI for NSTEMI or documented ischemia has been shown to significantly decrease the 30 day composite of death, MI, and unplanned revascularization compared to placebo in a prospective randomized trial. There were no deaths in any of the two groups and the primary end point was driven by peripro-
cedural myocardial infarction in concordance to the previously published studies.384

In conclusion, intensive (target LDL values optimally <70 mg/dL) statin treatment should be initiated within the first 24 hours after onset of an ACS event (eg, immediately after hospital admission) in all patients presenting with any form of ACS unless strictly contraindicated (eg, by proven intolerance) (Class I, LOE A).

It is reasonable to use statin pretreatment for patients who will be undergoing elective or urgent angioplasty in order to decrease perioperative myocardial infarction. There are no reports on risk or safety considerations of early initiation of statin treatment in ACS.

Glucose-Insulin-Potassium
Although glucose-insulin-potassium (GIK) therapy was formerly thought to reduce the chance of mortality during AMI by several mechanisms, recent clinical trials found that GIK did not show any benefit in STEMI.385,386 At this time there is little evidence to suggest that this intervention is helpful (Class IIb, LOE C).

Management of Arrhythmias
This section discusses management of arrhythmias during acute ischemia and infarction.

Ventricular Rhythm Disturbances
Treatment of ventricular arrhythmias during and after AMI has been a controversial topic for three decades. Primary VF accounts for the majority of early deaths during AMI.387–389 The incidence of primary VF is highest during the first 4 hours after onset of symptoms28,390–392 but remains an important contributor to mortality during the first 24 hours. Secondary VF occurring in the setting of CHF or cardiogenic shock can also contribute to death from AMI. VF is a less common cause of death in the hospital setting with the use of fibrinolytics and percutaneous revascularization as early reperfusion strategies. Broad use of β-blockers also contributes significantly in the reduction of VF incidence in the after AMI.

Although prophylaxis with lidocaine reduces the incidence of VF, an analysis of data from ISIS-3 and a meta-analysis suggest that lidocaine increased all-cause mortality rates.393 Thus, the practice of prophylactic administration of lidocaine is not recommended (Class III, LOE A).

Sotalol has not been adequately studied (Class IIb, LOE C).

Amiodarone in a single RCT did not appear to improve survival in low doses and may increase mortality in high doses when used early in patients with suspected myocardial infarction (Class IIb, LOE C).394

Twenty published studies including 14 RCTs and 4 meta-analyses/reviews provide no good evidence that prophyllactic antiarrhythmics improve outcomes (survival to discharge, 30/60 day mortality) and despite a documented decrease in the incidence of malignant ventricular arrhythmias, they may cause harm. Therefore prophylactic antiarrhythmics are not recommended for patients with suspected ACS or myocardial infarction in the prehospital or ED (Class III, LOE A).

Routine IV administration of β-blockers to patients without hemodynamic or electric contraindications is associated with a reduced incidence of primary VF (Class IIb, LOE C).

Low serum potassium, but not magnesium, has been associated with ventricular arrhythmias. It is prudent clinical practice to maintain serum potassium ≥4 mEq/L and magnesium >2 mEq/L (Class IIB, LOE A).

Routine administration of magnesium to patients with MI has no significant clinical mortality benefit, particularly in patients receiving fibrinolytic therapy.183 ISIS-4 enrolled >58 000 patients and showed a trend toward increased mortality rates when magnesium was given in-hospital for primary prophylaxis to patients within the first 4 hours of known or suspected AMI.

Following an episode of VF, there is no conclusive data to support the use of lidocaine or any particular strategy for preventing VF recurrence. Further management of ventricular rhythm disturbances is discussed in Part 8.2: “Management of Cardiac Arrest” and Part 8.3: “Management of Symptomatic Bradycardia and Tachycardia.”

Summary
There has been tremendous progress in reducing disability and death from ACS. But many patients still die before reaching the hospital because patients and family members fail to recognize the signs of ACS and fail to activate the EMS system. Once the patient with ACS contacts the healthcare system, providers must focus on support of cardiorespiratory function, rapid transport, and early classification of the patient based on ECG characteristics. Patients with STEMI require prompt reperfusion; the shorter the interval from symptom onset to reperfusion, the greater the benefit. In the STEMI population, mechanical reperfusion with percutaneous coronary intervention improves survival and decreases major cardiovascular events compared to fibrinolysis. Patients with UA/NSTEMI (non-STEMI ACS) or nonspecific or normal ECGs require risk stratification and appropriate monitoring and therapy. Healthcare providers can improve survival rates and myocardial function of patients with ACS by providing skilled, efficient, and coordinated out-of-hospital and in-hospital care.
## Disclosures

### Guidelines Part 10: ACS Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research</th>
<th>Speakers’ Bureau/Honoraria</th>
<th>Ownership</th>
<th>Consultant/Hospitality</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert E. O'Connor</td>
<td>University of Virginia Health System-Professor and Chair of Emergency Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William Brady</td>
<td>University of Virginia</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steven C. Brooks</td>
<td>University of Toronto—Clinician-Scientist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Deborah Dietersen</td>
<td>University of California, Davis Medical Center-Professor of Emergency Medicine</td>
<td>*Collaborator on Research Grant Nansphere and Heartscape with money going to the University</td>
<td>None</td>
<td>*Speakers Bureau for Sanofi-Aventis and Bristol-Myer Squibb</td>
<td>None</td>
<td>*Schoening Plough, Sanofi-Aventis</td>
<td>None</td>
</tr>
<tr>
<td>Jonathan Egan</td>
<td>Children's Hospital at Westmead, Sydney-Paediatric Intensivist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Chris Ghaemmaghami</td>
<td>University of Virginia School of Medicine Faculty Department of Emergency Medicine; Associate Professor and Vice Chair</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vena Menon</td>
<td>Cleveland Clinic—Director (CDI)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brian J. O'Neil</td>
<td>Wayne State, Associate Chair</td>
<td>*Medicor, Corporation, Zoll Circulation, Heartscape Technologies</td>
<td>None</td>
<td>*Sorin(continues)</td>
<td>None</td>
<td>*Sanofi-Aventis, Bristol-Myer Squibb</td>
<td>None</td>
</tr>
<tr>
<td>Andrew H. Travers</td>
<td>Emergency Health Services–Provincial Medical Director, Dalhousie; University–Associate Professor; GE-8 Hospital–Attending Physician</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dimitris Yannopoulos</td>
<td>University of Minnesota—Interventional cardiologist</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.  †Significant.

### References


38. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction treated with thrombolysis. Am J Cardiol. 2002;89:381–385.


angiina. Chest Pain Evaluation in the Emergency Room (CHEER) Investiga-
141. Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Handler
143. Caragher TE, Fernandez BB, Barr LA. Long-term experience with an
144. Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Handler
145. Gomez MA, Anderson JL, Karagounis LA, Muhlestein JB, Mooers FB.
146. Lee TH, Juarez G, Cook EF, Weisberg MC, Rouan GW, Brand DA,
147. Ramakrishna G, Milavetz JJ, Zinsmeister AR, Farkouh ME, Evans RW,
148. Zalenski RJ, McCarren M, Roberts R, Rydman RJ, Jovanovic B, Das K,
149. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,
150. Zalenski RJ, McCarren M, Roberts R, Rydman RJ, Jovanovic B, Das K,
151. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,
152. Zalenski RJ, McCarren M, Roberts R, Rydman RJ, Jovanovic B, Das K,
153. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,
154. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,
155. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,
156. Forberg JL, Hilmersson CE, Carlsson M, Arheden H, Bjork J, Hjalte K,


266. Murphy SA, Antman EM, Wittsott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCallie CH, Braunwald E. Reduction in recurrent cardiovascular events with prasugrel compared with clopi-


Colquhoun MC, Julien DG. Sudden death in the community—the arrhythmia causing cardiac arrest and results of immediate resuscitation. *Resuscitation.* 1992;24:177A.

Campbell RW, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction: natural history study. *Br Heart J.* 1988;61:198–205. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

